Galderma buys CollaGenex in $420M deal

A subsidiary of Galderma Pharma will buy CollaGenex Pharmaceuticals--which makes Oracea for rosacea--in a deal that values the company at $420 million. Galderma Laboratories will pay $16.60 a share for CollaGenex, which will become a subsidiary of Galderma. Both boards have blessed the deal. Executives called it a marriage of complementary therapies.

"Galderma was the first pharmaceutical company to develop a topical product indicated for the treatment of rosacea," said Colin Stewart, CEO of CollaGenex. "Oracea, combined with the successful development of Col-118, will enable Galderma to offer physicians and patients a full suite of complementary pharmaceutical products to treat rosacea.'

- see this release
- read the AFX report for more

Related Articles:
CollaGenex bails on rosacea therapy. Report
CollaGenex touts Phase IV Oracea data. Report
FDA OKs Oracea for rosacea skin condition. Report
Researchers find cause, therapies for rosacea. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.